GLP-1-GIP-lanifibranor, a novel quintuple agonist, significantly reduces obesity and hyperglycemia in mice without typical PPAR side effects.

Current treatments for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH) often involve incretin-based therapies like GLP-1RAs or dual GLP-1R/GIPR agonists. While effective, systemic activation of nuclear receptors like PPARs (Peroxisome Proliferator-Activated Receptors) can lead to significant adverse effects, including anemia and fluid retention. This limits their broader clinical utility. There's a critical need for targeted polypharmacology that can leverage synergistic pathways while mitigating off-target systemic exposure, addressing the gap in safer, more comprehensive metabolic therapeutics.

Researchers developed GLP-1-GIP-lanifibranor, a unimolecular conjugate combining GLP-1R/GIPR co-agonism with pan-PPAR activation. This compound was evaluated in obese mouse models (specific N and dose not provided in abstract). The conjugate's efficacy was compared against semaglutide, GLP-1-GIP co-agonism, and lanifibranor alone. Primary endpoints included body weight, adiposity, food intake, hyperglycemia, and insulin sensitivity. Mechanistic analyses utilized receptor-dependent delivery studies and investigated PPARδ signaling, alongside assessments for classical PPAR-related adverse effects.

The novel conjugate, GLP-1-GIP-lanifibranor, produced greater reductions in body weight, adiposity, food intake, and hyperglycemia compared to semaglutide, GLP-1-GIP co-agonism, or lanifibranor alone in obese mouse models. It also significantly improved insulin sensitivity. Mechanistic analyses confirmed receptor-dependent delivery of lanifibranor to incretin receptor-expressing cells. Importantly, PPARδ signaling was identified as a principal mediator of glycemic improvement, operating independently of weight loss. This suggests a distinct mechanism contributing to its metabolic benefits. A key safety finding was the absence of typical PPAR-related side effects:

Unlike unconjugated lanifibranor, GLP-1-GIP-lanifibranor did not induce anemia, fluid retention, renal dysfunction, or adipocyte differentiation, supporting the concept that tissue-restricted PPAR activation may mitigate classical adverse effects of systemic PPAR agonism.